Last week, the UK Supreme Court held a four-day hearing on an issue that should help to determine the level of evidence pharmaceutical companies will have to provide to demonstrate the “plausibility” of a patent claim, particularly one that applies to second medical use patents.
As well hopefully elucidating the evidence required for plausibility, the ruling on this case, which involves Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?